3篇
您的检索式：作者名="Tim F.Greten"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Immunobiology and immunotherapy of HCC:spotlight on innate and innate-like immune cells显示文摘Immune-based therapies such as immune checkpoint inhibitors have revolutionized the systemic treatment of various cancer types.The therapeutic application of monoclonal antibodies targeting inhibitory pathways such as programmed cell death-1(PD-1)/programmed cell death ligand 1(PD-L1)and CTLA-4 to cells of the adaptive immune system has recently been shown to generate meaningful improvement in the clinical outcome of hepatocellular carcinoma(HCC).Nevertheless,current immunotherapeutic approaches induce durable responses in only a subset of HCC patients.Since immunologic mechanisms such as chronic inflammation due to chronic viral hepatitis or alcoholic and nonalcoholic fatty liver disease play a crucial role in the initiation,development,and progression of HCC,it is important to understand the underlying mechanisms shaping the unique tumor microenvironment of liver cancer.The liver is an immunologic organ with large populations of innate and innate-like immune cells and is exposed to bacterial,viral,and fungal antigens through the gut-liver axis.Here,we summarize and highlight the role of these cells in liver cancer and propose strategies to therapeutically target them.We also discuss current immunotherapeutic strategies in HCC and outline recent advances in our understanding of how the therapeutic potential of these agents might be enhanced. | Benjamin Ruf Bernd Heinrich Tim F.Greten | 2021 | Cellular & Molecular Immunology2021，18，1： | 18 |
| 2 | 肝细胞癌的免疫治疗(上)显示文摘肝细胞癌(HCC)是世界第五大常见肿瘤,5年生存率低于5%,每年至少100万新发病例。其中一小部分病人可能适合外科切除或者局部消融治疗。但是,这些治疗受到肿瘤大小、肝脏储备功能和肝内转移的限制。因此,对于绝大多数晚期HCC患者来说,这些有望治愈的治疗手段都是不可能的。肝动脉化疗栓塞术(TACE)延长了已无条件行外科手术切除、肝移植或肿瘤消融治疗的患者的生存期,但是只有那些肝功能适当的患者才能够进行此项治疗。因为HCC患者基本上都有肝硬化基础,全身化疗耐受性较差,并且效果不佳。因此,根据全球性的指南(EASL或AASLD),像免疫治疗一类的备选方案最近正在晚期HCC患者中进行评估。 | Tim F.Greten Michael P.Manns Firouzeh Korangy 姚勤伟(编译) 杨月(审校) | 2007 | 传染病网络动态2007，，1： | 0 |
| 3 | 肝细胞癌的免疫治疗(下)显示文摘5.肿瘤逃逸机制
肿瘤从免疫系统产生了很多逃逸机制来抑制抗肿瘤反应。产生免疫抑制因子、增加调节性T细胞、下调肿瘤抗原和MHC分子都是肿瘤细胞用以逃避免疫识别的机制。已有很清楚的证据显示发生HCC能导致肿瘤特异性免疫反应受到抑制。尤其是我们已经证实尽管在超过50%的HCC患者中检测到肿瘤特异性的细胞和体液免疫反应,但是HCC仍然有所进展。虽然有抗原特异性T细胞的出现但HCC肿瘤仍然进展,这增加了对免疫治疗该肿瘤的有效性的关注。因为下面会展示,HCC的发展导致一系列不同的免疫机制,结果就是HCC患者中肿瘤特异性免疫反应的抑制。 | Tim F.Greten Michael P.Manns Firouzeh Korangy 姚勤伟(编译) 杨月(审校) | 2007 | 传染病网络动态2007，，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员